Literature DB >> 27792461

Anti-coxsackievirus B4 (CV-B4) enhancing activity of serum associated with increased viral load and pathology in mice reinfected with CV-B4.

Firas Elmastour1,2,3, Hela Jaïdane2,3, Mehdi Benkahla1, Leila Aguech-Oueslati1,2, Famara Sane1, Aymen Halouani2,3, Ilka Engelmann1, Antoine Bertin1, Moncef Mokni4, Jawhar Gharbi2, Mahjoub Aouni2, Enagnon K Alidjinou1, Didier Hober1.   

Abstract

In previous studies it was shown that inoculation of Swiss albino mice with CV-B4 E2 resulted in the production of serum IgG capable of enhancing the CV-B4 E2 infection of murine spleen cells cultures. To investigate whether such an enhancing activity of serum can play a role in vivo, we decided to study the CV-B4 E2 infection in mice exposed to successive inoculations of virus. In Swiss albino mice infected with CV-B4 E2 at the age of 21 days, anti-CV-B4 E2 neutralizing and enhancing activities of their serum peaked after 55 d. In contrast, mice inoculated at the age of 55 d expressed much lower activities. Despite the neutralizing activity of serum, CV-B4 E2 inoculated a second time to 55 day-old animals spread into the host. At the age of 72 and 89 d the levels of viral RNA and infectious particles were higher in organs of animals exposed to 2 successive infections compared with animals infected once at the age of 21 d or 55 d. In animals with 2 successive inoculations of CV-B4 E2 there was a relationship between the anti-CV-B4 E2 enhancing activity of serum and the level of viral RNA in organs and an enhancement of pathology was observed as displayed by histological analysis of pancreas and hyperglycaemia. Altogether our data strongly suggest that an anti-CV-B4 E2 enhancing activity in the host can play a role in the outcome of a secondary infection with this virus.

Entities:  

Keywords:  enterovirus; hyperglycaemia; in vivo; pancreas; reinfection

Mesh:

Substances:

Year:  2016        PMID: 27792461      PMCID: PMC5626334          DOI: 10.1080/21505594.2016.1252018

Source DB:  PubMed          Journal:  Virulence        ISSN: 2150-5594            Impact factor:   5.882


  25 in total

1.  Secondary heterotypic versus homotypic infection by Coxsackie B group viruses: impact on early and late histopathological lesions and virus genome prominence.

Authors:  J Z Yu; J E Wilson; S M Wood; R Kandolf; K Klingel; D Yang; B M McManus
Journal:  Cardiovasc Pathol       Date:  1999 Mar-Apr       Impact factor: 2.185

2.  Coxsackievirus-mediated hyperglycemia is enhanced by reinfection and this occurs independent of T cells.

Authors:  Marc S Horwitz; Alex Ilic; Cody Fine; Enrique Rodriguez; Nora Sarvetnick
Journal:  Virology       Date:  2003-09-30       Impact factor: 3.616

3.  Enhancement of coxsackievirus B3 infection by antibody to a different coxsackievirus strain.

Authors:  Jaskamal Girn; Mojgan Kavoosi; Janet Chantler
Journal:  J Gen Virol       Date:  2002-02       Impact factor: 3.891

Review 4.  Immunology in the clinic review series; focus on type 1 diabetes and viruses: role of antibodies enhancing the infection with Coxsackievirus-B in the pathogenesis of type 1 diabetes.

Authors:  D Hober; F Sane; H Jaïdane; K Riedweg; A Goffard; R Desailloud
Journal:  Clin Exp Immunol       Date:  2012-04       Impact factor: 4.330

5.  Viral protein VP4 is a target of human antibodies enhancing coxsackievirus B4- and B3-induced synthesis of alpha interferon.

Authors:  Wassim Chehadeh; Pierre-Emmanuel Lobert; Pierre Sauter; Anne Goffard; Bernadette Lucas; Jacques Weill; Marie-Christine Vantyghem; Gunnar Alm; Pascal Pigny; Didier Hober
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

6.  Monocytes of Patients with Type 1 Diabetes Harbour Enterovirus RNA.

Authors:  Enagnon Kazali Alidjinou; Wassim Chehadeh; Jacques Weill; Marie-Christine Vantyghem; Chantal Stuckens; Anne Decoster; Christine Hober; Didier Hober
Journal:  Eur J Clin Invest       Date:  2015-08-06       Impact factor: 4.686

7.  Secondary enterovirus infection in the murine model of myocarditis. Pathologic and immunologic aspects.

Authors:  M A Beck; N M Chapman; B M McManus; J C Mullican; S Tracy
Journal:  Am J Pathol       Date:  1990-03       Impact factor: 4.307

8.  Infection of primary cultures of murine splenic and thymic cells with coxsackievirus B4.

Authors:  Hela Jaïdane; Jawhar Gharbi; Pierre-Emmanuel Lobert; Delphine Caloone; Bernadette Lucas; Famara Sané; Thierry Idziorek; Marie-Bénédicte Romond; Mahjoub Aouni; Didier Hober
Journal:  Microbiol Immunol       Date:  2008-01       Impact factor: 1.955

Review 9.  Mechanisms and results of the antibody-dependent enhancement of viral infections and role in the pathogenesis of coxsackievirus B-induced diseases.

Authors:  Pierre Sauter; Didier Hober
Journal:  Microbes Infect       Date:  2009-04       Impact factor: 2.700

10.  The coxsackie- and adenovirus receptor (CAR) is an in vivo marker for epithelial tight junctions, with a potential role in regulating permeability and tissue homeostasis.

Authors:  Elisabeth Raschperger; Johan Thyberg; Sven Pettersson; Lennart Philipson; Jonas Fuxe; Ralf F Pettersson
Journal:  Exp Cell Res       Date:  2006-03-15       Impact factor: 3.905

View more
  9 in total

Review 1.  Persistent coxsackievirus B infection and pathogenesis of type 1 diabetes mellitus.

Authors:  Magloire Pandoua Nekoua; Enagnon Kazali Alidjinou; Didier Hober
Journal:  Nat Rev Endocrinol       Date:  2022-06-01       Impact factor: 47.564

2.  Evaluation of Contamination Risks with Coxsackievirus B4 E2 in Swiss Albino Mice Stools.

Authors:  Leïla Aguech-Oueslati; Hela Jaidane; Famara Sane; Nedia Jrad-Battikh; Sabrine Ben Hamed; Didier Hober; Jawhar Gharbi
Journal:  Curr Microbiol       Date:  2017-08-30       Impact factor: 2.188

3.  Coxsackievirus B4 vertical transmission in a murine model.

Authors:  Hela Jaïdane; Aymen Halouani; Habib Jmii; Firas Elmastour; Moncef Mokni; Mahjoub Aouni
Journal:  Virol J       Date:  2017-01-31       Impact factor: 4.099

4.  Prior immune exposure can protect or can enhance pathology in the enteroviruses: what predicts the outcome?

Authors:  Nora M Chapman
Journal:  Virulence       Date:  2016-12-09       Impact factor: 5.882

Review 5.  Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes.

Authors:  Jessica L Dunne; Sarah J Richardson; Mark A Atkinson; Maria E Craig; Knut Dahl-Jørgensen; Malin Flodström-Tullberg; Heikki Hyöty; Richard A Insel; Åke Lernmark; Richard E Lloyd; Noel G Morgan; Alberto Pugliese
Journal:  Diabetologia       Date:  2019-01-23       Impact factor: 10.122

Review 6.  Molecular Pathogenicity of Enteroviruses Causing Neurological Disease.

Authors:  Anna Majer; Alan McGreevy; Timothy F Booth
Journal:  Front Microbiol       Date:  2020-04-09       Impact factor: 5.640

Review 7.  Effect of Coxsackievirus B4 Infection on the Thymus: Elucidating Its Role in the Pathogenesis of Type 1 Diabetes.

Authors:  Abdulaziz Alhazmi; Magloire Pandoua Nekoua; Hélène Michaux; Famara Sane; Aymen Halouani; Ilka Engelmann; Enagnon Kazali Alidjinou; Henri Martens; Hela Jaidane; Vincent Geenen; Didier Hober
Journal:  Microorganisms       Date:  2021-05-29

Review 8.  Human Endogenous Retroviruses and Type 1 Diabetes.

Authors:  Sandrine Levet; B Charvet; A Bertin; A Deschaumes; H Perron; D Hober
Journal:  Curr Diab Rep       Date:  2019-11-21       Impact factor: 4.810

9.  Enterovirus D68-Associated Acute Flaccid Myelitis, United States, 2020.

Authors:  Sarah Kidd; Adriana S Lopez; Jennifer L Konopka-Anstadt; W Allan Nix; Janell A Routh; M Steven Oberste
Journal:  Emerg Infect Dis       Date:  2020-08-24       Impact factor: 6.883

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.